A new model to predict survival in colorectal cancer

September 03, 2020

Colorectal cancer (CRC) is the third most common cancer among women and men in the USA, and recent studies have shown an increasing incidence in less developed regions, including Sub-Saharan Africa (SSA). A team of researchers from South African universities in collaboration with the University of South Carolina-Upstate, have developed method which relies on a hybrid signature (based on patterns in DNA mutation and RNA expression) and assessed its predictive properties for the mutation status and survival of CRC patients.

The research team, led by Mohanad Mohammed at the University of KwaZulu-Natal, South Africa investigated publicly-available microarray and RNASeq data from 54 matched formalin-fixed paraffin embedded (FFPE) samples from the Affymetrix GeneChip and RNASeq platforms. The samples were used to obtain information about differentially expressed genes between mutant and wild-type samples. The researchers then applied bioinformatics techniques which include the use of support-vector machines, artificial neural networks, random forests, k-nearest neighbor, naïve Bayes, negative binomial linear discriminant analysis, and the Poisson linear discriminant analysis algorithms for classification. The Cox proportional hazards model was used for survival analysis.

When compared to the gene list from each of the individual platforms, the researchers noted that the hybrid gene list had the highest accuracy, sensitivity, specificity, and AUC for mutation status, across all the classifiers and is prognostic for survival in patients with CRC. Negative binomial linear discriminant analysis method was the best performer on the RNASeq data while the SVM method was the most suitable classifier for CRC across the two data types. The researchers concluded that nine genes were found to be predictive of survival.

"This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.", notes Mohammed. Future studies should determine the effectiveness of integration in cancer survival analysis and the application on unbalanced data, where the classes are of different sizes, as well as on data with multiple classes. The research has been published in the journal, Current Bioinformatics.
For more information, please visit: https://www.eurekaselect.com/node/183657/article/colorectal-cancer-classification-and-survival-analysis-based-on-an-integrated-rna-and-dna-molecular-signature

Authors: Mohanad Mohammed1, Henry Mwambi1, and Bernard Omolo2, 3

1School of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, South Africa 2Division of Mathematics & Computer Science, University of South Carolina-Upstate, USA 3School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Bentham Science Publishers

Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.